Cardinal Health, Inc.
In the published model solve dated 2026-Q2, anchored at $234.55, Cardinal Health, Inc. (CAH) is priced for +6.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Capital allocation is the clearest signal in this file: the share count has fallen about 4.2% a year over the four years to December 2025 while the payout crept higher, with the FY2025 10-K reporting that ⟦We paid cash dividends per common share of $2.02, $2.00, and $1.98 in fiscal 2025, 2024, and 2023, respectively.⟧ • Customer concentration is not a hypothetical risk here, because it has already happened once: the 10-K discloses that ⟦Sales to OptumRx generated 17 percent of our consolidated
Is CAH overvalued? See what's priced in →
1,388 institutional managers reported holding CAH in 13F filings for the quarter ended 2026-03-31. Together they hold about 84% of the company; the top 10 hold 43%. 132 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 9.0M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CAH has cut its share count 17.8% over the past five years, spending $5.28B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting); the current rate is $2.02 a share annually. Cash returned over the past three years: $1.24B in dividends and $2.28B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at CAH over the trailing three years. Absence is a fact about the company, not a signal. 20 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CAH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2022-05-06 | -3.7% | -9.2% |
| 2022-08-12 | +10.5% | -1.8% |
| 2022-11-05 | +5.1% | -1.1% |
| 2023-08-16 | -2.8% | +3.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CAH's latest 8-K filings: 2026-08-11 (items 2.02, 7.01, 9.01); 2026-08-11 (items 1.01, 1.02, 2.03, 9.01); 2026-08-05 (items 5.02); 2026-04-30 (items 2.02, 7.01, 9.01); 2026-03-23 (items 5.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.